Medicare GLP-1 Bridge Runs Outside Part D and Pharmacy Teams Need a Different Workflow

Medicare cannot cover anti-obesity medications under current law. Since July 1, 2026, a CMS demonstration called the GLP-1 Bridge has offered a workaround for eligible Part D beneficiaries, and it behaves nothing like a normal Part D claim.^1,2 Pharmacists who treat it like one will see rejected claims, confused patients and abandoned prescriptions.

What is the Bridge, and Who Qualifies?

CMS created the Bridge after its earlier BALANCE model stalled. BALANCE would have run through private Part D and Medicare Advantage plans starting in 2027, but too few plans agreed to participate. The Bridge replaced it. CMS runs the program directly, and it operates outside the standard Part D benefit.¹ It runs from July 1, 2026 through December 31, 2027.³

The program covers weight management only. Covered products are Wegovy (semaglutide; Novo Nordisk) injection and tablets, Zepbound (tirzepatide; Lilly) KwikPen and Foundayo (orforglipron; Lilly) tablets. The single-dose Zepbound pen and vials are not covered, and neither are Ozempic, Rybelsus (semaglutide; Novo Nordisk), Mounjaro (tirzepatide; Lilly) or Trulicity (dulaglutide; Lilly)² Patients who use a glucagon-like peptide-1 (GLP-1) for type 2 diabetes, obstructive sleep apnea (OSA), or other approved indications stay on their regular Part D pathway.^1,2

Who Qualifies for the Bridge?

Patients must be 18 years of age or older and enrolled in an eligible Part D plan. CMS sets the clinical thresholds by body mass index: 35 or higher; or 30 or higher with a qualifying condition, such as heart failure with preserved ejection fraction, uncontrolled hypertension despite 2 antihypertensives, or chronic kidney disease stage IIIa or higher; or 27 or higher with qualifying criteria, such as prediabetes. Patients with type 2 diabetes, moderate-to-severe OSA, metabolic dysfunction-associated steatohepatitis or established cardiovascular disease are excluded, as are patients already receiving a GLP-1 through Part D.²

Where Claims Break Down

The prescription decides which pathway the claim takes. Prescribers should include an obesity diagnosis code from the E66 family and add the note "Send to Bridge for weight management." Without that note, the pharmacy may bill the patient's Part D plan, where weight-loss drugs are typically not covered.²

When the pharmacy bills the Bridge, the first claim is expected to reject, and that rejection triggers the prior authorization (PA) request.² The pharmacy sends the PA form to the prescriber through CoverMyMeds or fax, usually within 24 to 72 hours. Prescribers should wait for that request rather than submitting a PA to CMS on their own. If nothing arrives within 72 hours, the prescriber can download the CMS form and fax it. Decisions return to the prescriber and patient within 72 hours of submission.² The PA goes to a central processor, not the patient's plan, and WTW reports that Humana handles these requests.¹ After the first fill is approved, refills do not need a new PA unless the patient switches to a different covered GLP-1.²

Pharmacy teams should build a short script for the first rejection so staff do not tell patients their drug is "not covered." The rejection is a step in the process.

What Patients Pay

Patients pay $50 per month. That amount sits outside the usual Part D payment flow: the deductible does not apply, the payment does not count toward the out-of-pocket maximum, and low-income subsidy protections do not reduce it.^1,3 For a patient on a fixed income, $50 every month with no cap protection is a real barrier. WTW reports that CMS pays pharmacies $245 per 30-day supply.¹ Pharmacies should confirm reimbursement against the program's current instructions before stocking inventory.

Four checks for the counter include the following:

1. Confirm that the prescription says "Send to Bridge for weight management" and carries an E66 code before billing anything.
2. Confirm the product. A Zepbound vial or single-dose pen will not process under the Bridge.
3. Screen for exclusions—especially type 2 diabetes and sleep apnea—which route to Part D.
4. Tell the patient about the $50 copay and the PA timeline at the first contact, not after the claim rejects.

What Happens in 2028

The Bridge ends December 31, 2027.³ Congress has not changed the statutory exclusion on obesity drugs, and earlier efforts to do so have not succeeded.¹ Pharmacies that enroll patients now should plan for a coverage cliff. Patients who start therapy in 2026 and 2027 could face a gap in 2028 unless Congress or CMS acts. Pharmacists can prepare those patients by explaining the end date now and by comparing self-pay options such as LillyDirect and NovoCare Pharmacy. Self-pay purchases do not count toward deductibles or out-of-pocket limits, and a promotional starting price is not the cost of maintenance treatment.³

The Pharmacist’s Role

Pharmacists sit at the point where this program succeeds or fails. They catch the missing prescription note, flag the wrong product, explain the rejection and set the cost expectation. They also keep the indication and regimen intact and check refill timing to prevent supply gaps.³ A demonstration this narrow rewards teams that treat it as its own workflow with its own checklist.

REFERENCES

1. Levin-Scherz J. Medicare's GLP-1 Bridge Program: What Employers Need to Know. WTW. August 10, 2026. Accessed October 22, 2026. https://www.wtwco.com/en-us/insights/2026/08/medicares-glp-1-bridge-program-what-employers-need-to-know

2. GLP-1 Bridge Program. UnitedHealthcare Provider. August 11, 2026. Accessed October 22, 2026. https://www.uhcprovider.com/en/resource-library/news/2026/glp-1-bridge-program.html

3. Cabrera V, Goldman J. Pharmacists Improve Access, Safe Use of Obesity Medications. Drug Topics. October 13, 2026. Accessed October 22, 2026. https://www.drugtopics.com/view/pharmacists-improve-access-safe-use-of-obesity-medications